Cancer Drugs Market Predicted to Reach US$ 272 Bn by 2030 – Potential Opportunity is Opening in the Coming Year (2021-2030)

The global cancer drugs market size is forecasted to reach from US$ 146.58 billion in 2021 to US$ 272 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 7.2% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.

The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 and 2020, the forecast period considered is from 2021 to 2030. The cancer drugs market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1415

The global cancer drugs market growth driven by the rising prevalence of various types of cancer such as lungs cancer, colorectal cancer, bowel cancer, breast cancer, and various other types of cancer. The International Agency for Research on Cancer, in its report GLOBOCAN, has published that around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The lungs cancer was the most prominent cancer followed by the breast cancer.

Moreover, the increasing awareness regarding the availability of various new therapies to treat cancer is fueling the demand for the cancer drugs among the global cancer patients. Furthermore, the rising investments by the biopharmaceutical companies in the development of new cancer drugs and diagnostic devices are fostering the growth of the cancer drugs market. Moreover, the rising adoption of the health insurance and favorable reimbursement policies is encouraging the patients to adopt the latest therapies to treat cancer by providing them with financial support. This is further boosting the growth of the cancer drugs market across the globe.

Market Overview

The cancer drugs market study conducted by Precedence Research is intended at helping stakeholders get a comprehensive overview of potential challenges and undiscovered opportunities. The report offers exclusive insights to help companies make informed decision to sustain growth through the assessment period.

Scope of the Cancer Drugs Market

Report Coverage Details
Market Size in 2030 USD 272 Billion
Growth Rate CAGR of 7.2% from 2021 to 2030
Largest Market North America
Base Year 2021
Forecast Period 2021 to 2030

Competitive Landscape Analysis:

Some of the leading companies operating in the cancer drugs market are profiled in the market study. The report also underscores winning strategies adopted over the last few years and gauges impact of the same on growth trajectory exhibited by the market over the last few years.

Major companies operating in this report are

  • Amgen
  • Bayer Healthcare AG
  • CELGENE CORPORATION
  • GlaxoSmithKline
  • ARIAD Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Novartis
  • Hoffmann-La Roche Ltd.
  • AstraZeneca
  • BoehringerIngelheim GmbH
  • Pfizer
  • Teva Pharmaceuticals Industries

Market Dynamics

Driver

Rising prevalence of the cancer among the population

The most important and the most prominent driver of the cancer drugs is the growing prevalence of the cancer among the global population. The rapid developments in the field of biopharmaceuticals and the favorable reimbursement policies are significantly driving the demand for the cancer drugs among the population.

Restraint

High cost of the cancer drugs

The high cost associated with the cancer drugs is a major factor that may restrict the middle and low income people to adopt the expensive cancer therapies, especially in the underdeveloped and developing economies. Furthermore, the lack of awareness among the people is another factor that may hamper the market growth during the forecast period.

Opportunities

The increasing adoption of healthcare insurance

The high costs related to the healthcare and rising burden of diseases and infections across the globe is encouraging the population to opt for a healthcare insurance. The various medical and financial support in the form of reimbursements and medical claims provided by the healthcare insurances is expected to drive the adoption of the cancer immunotherapy among the cancer patients across the globe.

Challenges

Lack of access to healthcare facilities

The low and inadequate healthcare infrastructure in the developing and the underdeveloped economies results in the low access to the healthcare facilities. In most of the cases, the people suffering from cancer remain undiagnosed and untreated. This is a major challenge to the market players that may restrict them to grow further.

Report Highlights

  • Based on the drug class, the targeted therapy dominated the market in 2020. The increased awareness regarding the benefits of the targeted therapy over the traditional chemotherapy has significantly boosted the adoption of the targeted therapy among the patients. Moreover, the targeted therapy only targets the cancer cells and avoids the normal cells, which results in low side-effects. The efficiency of the targeted therapy in the treatment of the cancer cells has fostered the growth of this segment especially in the developed markets like North America and Europe.
  • Based on the indication, the breast cancer is estimated to be the most opportunistic segment during the forecast period. The breast cancer has become the most diagnosed cancer by surpassing the lungs cancer in 2020. According to the International Agency for Research on Cancer, the breast cancer accounted for over 10% of the global cancer cases in 2020. Hence, the rising prevalence of the breast cancer among the global female population is expected to drive the market growth in the foreseeable future.

Regional Snapshot

North America dominated the global cancer drugs market in 2020. The increased prevalence of the cancer, higher healthcare expenditure, increasing awareness regarding the new biopharmaceutical drugs, presence of the world’s top drug manufacturers, and the presence of sophisticated and developed healthcare infrastructure in the region are the major drivers of the cancer drugs market in North America. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020.

Europe is estimated to be the fastest-growing market in 2020. The Europe is characterized by the rapidly growing incidences of cancer, increased disposable income, growing health awareness, and rising demand for the advanced therapies.

Market Segmentation

By Drug Class

  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy

By Indication

  • Lungs Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Liver Cancer
  • Bladder Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Others

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Why should you invest in this report?

If you are aiming to enter the global cancer drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cancer drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1415

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Drugs Market 

5.1. COVID-19 Landscape: Cancer Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Drugs Market, By Drug Class

8.1. Cancer Drugs Market, by Drug Class Type, 2021-2030

8.1.1. Targeted Therapy

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Chemotherapy

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Hormonal Therapy

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Immunotherapy

8.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Cancer Drugs Market, By Indication

9.1. Cancer Drugs Market, by Indication, 2021-2030

9.1.1. Lungs Cancer

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Colorectal Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Breast Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Liver Cancer

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Bladder Cancer

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Head & Neck Cancer

9.1.6.1. Market Revenue and Forecast (2019-2030)

9.1.7. Prostate Cancer

9.1.7.1. Market Revenue and Forecast (2019-2030)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Cancer Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.1.2. Market Revenue and Forecast, by Indication (2019-2030)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.1.3.2. Market Revenue and Forecast, by Indication (2019-2030)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Indication (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.2.2. Market Revenue and Forecast, by Indication (2019-2030)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.2.3.2. Market Revenue and Forecast, by Indication (2019-2030)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Indication (2019-2030)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Indication (2019-2030)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Indication (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.3.2. Market Revenue and Forecast, by Indication (2019-2030)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.3.3.2. Market Revenue and Forecast, by Indication (2019-2030)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Indication (2019-2030)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Indication (2019-2030)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Indication (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.4.2. Market Revenue and Forecast, by Indication (2019-2030)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.4.3.2. Market Revenue and Forecast, by Indication (2019-2030)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Indication (2019-2030)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Indication (2019-2030)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Indication (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.5.2. Market Revenue and Forecast, by Indication (2019-2030)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.5.3.2. Market Revenue and Forecast, by Indication (2019-2030)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Indication (2019-2030)

Chapter 11. Company Profiles

11.1. Amgen

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Bayer Healthcare AG

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. CELGENE CORPORATION

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. GlaxoSmithKline

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. ARIAD Pharmaceuticals, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Eli Lilly and Company

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Novartis

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Hoffmann-La Roche Ltd.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. AstraZeneca

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. BoehringerIngelheim GmbH

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report @ https://www.precedenceresearch.com/checkout/1415

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.